• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人凝血因子V中Asn2181的部分糖基化作为分子和功能异质性的原因。通过对N-连接糖基化共有序列进行诱变来调节糖基化效率。

Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.

作者信息

Nicolaes G A, Villoutreix B O, Dahlbäck B

机构信息

Wallenberg Laboratory, Department of Clinical Chemistry, Malmö University Hospital, Lund University, Sweden.

出版信息

Biochemistry. 1999 Oct 12;38(41):13584-91. doi: 10.1021/bi991165r.

DOI:10.1021/bi991165r
PMID:10521265
Abstract

Coagulation factor V (FV) circulates in two forms, FV1 and FV2, having slightly different molecular masses and phospholipid-binding properties. The aim was to determine whether this heterogeneity is due to the degree of glycosylation of Asn(2181). FVa1 and FVa2 were isolated and digested with endoglycosidase PNGase F. As judged by Western blotting, the FVa2 light chain contained two N-linked carbohydrates, whereas FVa1 contained three. Wild-type FV and three mutants, Asn(2181)Gln, Ser(2183)Thr, and Ser(2183)Ala, were expressed in COS1 cells, activated by thrombin, and analyzed by Western blotting. Wild-type FVa contained the 71 kDa-74 kDa doublet, whereas the Asn(2181)Gln and Ser(2183)Ala mutants contained only the 71 kDa light chain. In contrast, the Ser(2183)Thr mutant gave a 74 kDa light chain. This demonstrated that the third position in the Asn-X-Ser/Thr consensus affects glycosylation efficiency, Thr being associated with a higher degree of glycosylation than Ser. The Ser(2183)Thr mutant FVa was functionally indistinguishable from plasma-purified FVa1, whereas Asn(2181)Gln and Ser(2183)Ala mutants behaved like FVa2. Thus, the carbohydrate at Asn(2181) impaired the interaction between FVa and the phospholipid membrane, an interpretation consistent with a structural analysis of a three-dimensional model of the C2 domain and the position of a proposed phospholipid-binding site. In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.

摘要

凝血因子V(FV)以两种形式循环,即FV1和FV2,它们的分子量和磷脂结合特性略有不同。目的是确定这种异质性是否归因于Asn(2181)的糖基化程度。分离出FVa1和FVa2并用内切糖苷酶PNGase F消化。通过蛋白质印迹法判断,FVa2轻链含有两个N-连接的碳水化合物,而FVa1含有三个。野生型FV和三个突变体Asn(2181)Gln、Ser(2183)Thr和Ser(2183)Ala在COS1细胞中表达,经凝血酶激活后用蛋白质印迹法分析。野生型FVa含有71 kDa - 74 kDa的双峰,而Asn(2181)Gln和Ser(2183)Ala突变体仅含有71 kDa的轻链。相反,Ser(2183)Thr突变体产生74 kDa的轻链。这表明Asn-X-Ser/Thr共有序列中的第三位影响糖基化效率,与Ser相比,Thr与更高程度的糖基化相关。Ser(2183)Thr突变体FVa在功能上与血浆纯化的FVa1无法区分,而Asn(2181)Gln和Ser(2183)Ala突变体的行为与FVa2相似。因此,Asn(2181)处的碳水化合物损害了FVa与磷脂膜之间的相互作用,这一解释与C2结构域三维模型的结构分析以及拟议的磷脂结合位点的位置一致。总之,我们表明FV1 - FV2异质性是由Asn(2181)的差异糖基化引起的,这与糖基化共有序列第三位存在Ser而非Thr有关。

相似文献

1
Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.人凝血因子V中Asn2181的部分糖基化作为分子和功能异质性的原因。通过对N-连接糖基化共有序列进行诱变来调节糖基化效率。
Biochemistry. 1999 Oct 12;38(41):13584-91. doi: 10.1021/bi991165r.
2
Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.人凝血因子V第二个C型结构域天冬酰胺-2181位点的部分糖基化调节凝血酶原酶复合物的组装。
Biochemistry. 1999 Aug 31;38(35):11448-54. doi: 10.1021/bi991275y.
3
The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency.紧跟天冬酰胺- X -丝氨酸/苏氨酸序列之后的氨基酸是N -连接核心糖基化效率的重要决定因素。
Biochemistry. 1998 May 12;37(19):6833-7. doi: 10.1021/bi972217k.
4
The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181.与R2单倍型相关的人因子V轻链中的Asp2194Gly突变导致FV表达水平降低,但对Asn2181的糖基化没有影响。
Thromb Haemost. 2003 Mar;89(3):429-37.
5
Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction.凝血酶介导的因子 V 激活的结构基础:Glu666-Glu672 序列对于重链-B 结构域连接处的加工至关重要。
Blood. 2011 Jun 30;117(26):7164-73. doi: 10.1182/blood-2010-10-315309. Epub 2011 May 9.
6
An assay to quantify the two plasma isoforms of factor V.一种定量凝血因子V两种血浆同工型的检测方法。
Thromb Haemost. 2000 Dec;84(6):1066-71.
7
Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C.辅因子凝血因子V上的碳水化合物部分而非衍生的辅因子凝血因子Va,调节其被活化蛋白C的失活。
Biochemistry. 2002 Feb 5;41(5):1672-80. doi: 10.1021/bi011304g.
8
Exchange of Ser-4 for Val, Leu or Asn in the sequon Asn-Ala-Ser does not prevent N-glycosylation of the cell surface glycoprotein from Halobacterium halobium.在序列Asn-Ala-Ser中,将Ser-4替换为Val、Leu或Asn并不妨碍嗜盐栖热菌细胞表面糖蛋白的N-糖基化。
Glycobiology. 1998 Dec;8(12):1157-64. doi: 10.1093/glycob/8.12.1157.
9
Disruption of potential sites for N-linked glycosylation does not impair hormone binding to the lutropin/choriogonadotropin receptor if Asn-173 is left intact.如果天冬酰胺-173保持完整,N-连接糖基化潜在位点的破坏不会损害激素与促黄体生成素/绒毛膜促性腺激素受体的结合。
J Biol Chem. 1993 Jan 25;268(3):1513-6.
10
Functional properties of recombinant factor V mutated in a potential calcium-binding site.在潜在钙结合位点发生突变的重组因子V的功能特性
Biochemistry. 2004 May 18;43(19):5803-10. doi: 10.1021/bi0361362.

引用本文的文献

1
Plasma -Glycan Signatures Are Associated With a First Event of Venous Thromboembolism.血浆聚糖特征与静脉血栓栓塞的首次发作相关。
Arterioscler Thromb Vasc Biol. 2025 Sep;45(9):1693-1703. doi: 10.1161/ATVBAHA.125.323205. Epub 2025 Aug 7.
2
ptFVa ( Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C.凝血酶原酶复合物中的因子Va(蛇毒衍生的因子Va)在被活化蛋白C蛋白水解后保持结构完整性。
Arterioscler Thromb Vasc Biol. 2021 Aug;41(8):2263-2276. doi: 10.1161/ATVBAHA.121.316038. Epub 2021 Jun 24.
3
Comprehensive N- and O-glycosylation mapping of human coagulation factor V.
人凝血因子V的全面N-糖基化和O-糖基化图谱分析
J Thromb Haemost. 2020 Aug;18(8):1884-1892. doi: 10.1111/jth.14861. Epub 2020 Jun 14.
4
Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding.凝血因子 Va 的关键相互作用残基和区域,用于凝血酶原酶的组装和凝血酶原的结合。
J Thromb Haemost. 2019 Aug;17(8):1229-1239. doi: 10.1111/jth.14487. Epub 2019 Jun 17.
5
Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.质谱辅助鉴定 HLA-DR 和 HLA-DQ 上呈现的 ADAMTS13 衍生肽。
Haematologica. 2018 Jun;103(6):1083-1092. doi: 10.3324/haematol.2017.179119. Epub 2018 Mar 22.
6
Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.VIII 因子 C1 结构域的 2092-2093 和 2158-2159 位突刺包含了调节辅助因子功能和细胞摄取的区域。
J Biol Chem. 2013 Oct 11;288(41):29670-9. doi: 10.1074/jbc.M113.473116. Epub 2013 Sep 5.
7
α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.α(1,3)-岩藻糖基转移酶 FUT4 和 FUT7 控制小鼠对血栓形成的易感性。
Am J Pathol. 2013 Jun;182(6):2082-93. doi: 10.1016/j.ajpath.2013.02.010. Epub 2013 Apr 2.
8
Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes.Galectin-8 蛋白作为巨核细胞内吞凝血因子 V 的介质的新作用。
J Biol Chem. 2012 Mar 9;287(11):8327-35. doi: 10.1074/jbc.M111.305151. Epub 2012 Jan 20.
9
Mapping N-linked glycosylation sites in the secretome and whole cells of Aspergillus niger using hydrazide chemistry and mass spectrometry.利用酰肼化学和质谱法绘制黑曲霉 secretome 和 whole cells 中的 N-连接糖基化位点图谱。
J Proteome Res. 2012 Jan 1;11(1):143-56. doi: 10.1021/pr200916k. Epub 2011 Dec 2.
10
Inhibition of thrombin formation by active site mutated (S360A) activated protein C.活性位点突变(S360A)的活化蛋白 C 对凝血酶形成的抑制作用。
J Biol Chem. 2010 Jul 23;285(30):22890-900. doi: 10.1074/jbc.M110.131029. Epub 2010 May 18.